STTK Logo

Shattuck Labs, Inc. (STTK) 

NASDAQ
Market Cap
$57.99M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
224 of 776
Rank in Industry
129 of 433

Largest Insider Buys in Sector

STTK Stock Price History Chart

STTK Stock Performance

About Shattuck Labs, Inc.

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Insider Activity of Shattuck Labs, Inc.

Over the last 12 months, insiders at Shattuck Labs, Inc. have bought $126,999 and sold $369,558 worth of Shattuck Labs, Inc. stock.

On average, over the past 5 years, insiders at Shattuck Labs, Inc. have bought $39.91M and sold $12.26M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Schreiber Taylor (Chief Executive Officer) — $94,231. Brous Tyler (director) — $32,768.

The last purchase of 36,500 shares for transaction amount of $44,220 was made by Schreiber Taylor (Chief Executive Officer) on 2024‑10‑07.

List of Insider Buy and Sell Transactions, Shattuck Labs, Inc.

2024-10-07PurchaseChief Executive Officer
36,500
0.0249%
$1.21$44,220+19.47%
2024-06-28Purchasedirector
3,000
0.0065%
$3.90$11,7000.00%
2024-06-27Purchasedirector
5,416
0.0117%
$3.89$21,0680.00%
2024-06-26PurchaseChief Executive Officer
14,400
0.0278%
$3.47$50,011-8.71%
2024-03-06SaleSee Remarks
11,354
0.0266%
$10.53$119,558-34.57%
2024-01-10SaleChief Financial Officer
25,000
0.0527%
$10.00$250,000-21.20%
2022-04-26Purchase
28,330
0.0665%
$3.63$102,838-16.16%
2022-04-21Purchase
26,049
0.0621%
$3.69$96,121-15.89%
2022-01-19Purchasedirector
3,000
0.0073%
$6.87$20,610-48.05%
2022-01-18Purchasedirector
2,500
0.0061%
$7.01$17,525-48.97%
2022-01-14Purchasedirector
2,500
0.0058%
$7.16$17,900-52.05%
2021-10-19SaleGeneral Counsel
33,000
0.0774%
$19.50$643,500-78.12%
2021-07-15Saledirector
34
<0.0001%
$22.74$773-67.34%
2021-07-15SaleGeneral Counsel
2,000
0.0047%
$22.18$44,367-67.34%
2021-07-15SaleChief Financial Officer
2,000
0.0047%
$22.13$44,263-67.34%
2021-07-14Saledirector
12,049
0.0289%
$23.14$278,784-68.01%
2021-07-13Saledirector
4,356
0.0103%
$25.12$109,426-70.64%
2021-07-12Saledirector
2,829
0.0067%
$26.15$73,983-71.36%
2021-07-09Saledirector
3,276
0.0077%
$26.54$86,935-71.55%
2021-07-08Saledirector
3,586
0.0084%
$26.24$94,101-70.89%

Insider Historical Profitability

<0.0001%
Brous Tylerdirector
238088
0.4989%
$1.2250<0.0001%
Schreiber TaylorChief Executive Officer
71002
0.1488%
$1.22210
Redmile Group, LLC
5619914
11.7751%
$1.2210+49.69%
Golumbeski George
54613
0.1144%
$1.2220<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Fidelity Investments$63.66M14.987.12M+0.71%+$446,758.62<0.01
Redmile Group$50.2M11.815.62M-0.08%-$39,559.500.51
Prosight Management Lp$33.3M7.833.73M+33.86%+$8.42M9.28
Adage Capital Partners Gp L L C$21.19M4.982.37M+35.22%+$5.52M0.04
The Vanguard Group$16.27M3.831.82M+38.18%+$4.5M<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.